Search results for : ins - Cancerrxgene - Genomics of Drug Sensitivity in Cancer

Search Results for: ins

Drugs (6)

Name	Synonyms	Targets	Target Pathway	PubCHEM	Datatset	Sample size	Screening site
Dasatinib	BMS-354825-03, BMS-354825, Sprycel	ABL, SRC, Ephrins, PDGFR, KIT	RTK signaling	3062316	GDSC1	392	MGH
Dasatinib	BMS-354825-03, BMS-354825, Sprycel	ABL, SRC, Ephrins, PDGFR, KIT	Other, kinases	3062316	GDSC2	962	SANGER
Linsitinib	OSI-906, ASP-7487	IGF1R	IGF1R signaling	11640390	GDSC1	867	MGH
Linsitinib	OSI-906, ASP-7487	IGF1R	IGF1R signaling	11640390	GDSC2	966	SANGER
ascorbate (vitamin C)	back-up solution from YWKim	anti-oxidant proteins	Other		GDSC2	732	SANGER
glutathione	G6013, sigma	anti-oxidant proteins	Other		GDSC2	732	SANGER

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).